Low-Dose Nivolumab in Various Cancers: A Real-World Exploratory Analysis in Resource-Constrained Settings. (PubMed, Cancer Rep (Hoboken)) - Oct 20, 2026 - "Low-dose nivolumab shows preliminary efficacy in resource-constrained settings. Further research should explore optimal dosing and scheduling for low-dose immunotherapy and evaluate its efficacy and safety through larger, homogeneous studies."
Journal • Real-world evidence • Retrospective data • Inherited Retinal Dystrophy • Oncology • Ophthalmology
|
|
Abish Adhikari; Anjani Kr Jha; Gerim Prasai; Jeebana Bhandari; Rajani Jha; Simit Sapkota; Subhas Pandit; Sunil Shrestha
|